Brief: Transcode Therapeutics Gets Delisting Determination Letter From Nasdaq
04/08/2023 13:33
Aug 4 (Reuters) - Transcode Therapeutics Inc RNAZ.O :
* TRANSCODE THERAPEUTICS - JULY 26, GOT DELISTING
DETERMINATION
LETTER FROM NASDAQ STAFF ADVISING IT HAD DETERMINED NOT TO
ACCEPT CO'S COMPLIANCE PLAN
Further company coverage: RNAZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors